Increased expression of TRAIL receptor 3 on eosinophils in churg-strauss syndrome

Arthritis and Rheumatism

Volumn 56, Issue 2, 2007, Pages 662-673

  Mitsuyama, Hideo ^a   Matsuyama, Wataru ^a   Watanabe, Masaki ^a   Shirahama, Yuko ^a   Higashimoto, Ikkou ^a   Wada, Takashi ^b   Osame, Mitsuhiro ^a   Arimura, Kimiyoshi ^a  

^a KAGOSHIMA UNIVERSITY HOSPITAL   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CASPASE 3; CHROMIUM 51; GLUCOCORTICOID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; ASTHMA; CELL SURVIVAL; CHROMIUM 51 RELEASE; CHURG STRAUSS SYNDROME; CONTROLLED STUDY; EOSINOPHIL; EOSINOPHIL COUNT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; HYPEREOSINOPHILIA; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; PARASITOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; STATISTICAL ANALYSIS; T LYMPHOCYTE; VOLUNTEER; WESTERN BLOTTING;

ADULT; AGED; APOPTOSIS; ASTHMA; CASPASE 3; CHURG-STRAUSS SYNDROME; EOSINOPHILS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 33847017645     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22387     Document Type: Article

References (44)

1. Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003;361:587-94.
2. Conron M, Beynon HL. Churg-Strauss syndrome. Thorax 2000;55:870-7.
3. Corrigan CJ, Kay AB. T cells and eosinophils in the pathogenesis of asthma. Immunol Today 1992;13:501-7.
4. Drage LA, Davis MD, De Castro F, Van Keulen V, Weiss EA, Gleich GJ, et al. Evidence for pathogenic involvement of eosinophils and neutrophils in Churg-Strauss syndrome. J Am Acad Dermatol 2002;47:209-16.
5. Kita H, Abu-Ghazaleh RI, Sur S, Gleich GJ. Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils. J Immunol 1995;154:4749-58.
6. Gleich GJ, Frigas E, Loegering DA, Wassom DL, Steinmuller D. Cytotoxic properties of the eosinophil major basic protein. J Immunol 1979;123:2925-7.
7. Muschen M, Warskulat U, Perniok A, Even J, Moers C, Kismet B, et al. Involvement of soluble CD95 in Churg-Strauss syndrome. Am J Pathol 1999;155:915-25.
8. Gross WL. Churg-Strauss syndrome: update on recent developments. Curr Opin Rheumatol 2002;14:11-4.
9. Hellmich B, Ehlers S, Csernok E, Gross WL. Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2003;21(6 Suppl 32):S69-77.
10. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
11. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
12. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8.
13. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186:1165-70.
14. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21.
15. Pan G, Ni J, Yu G, Wei YF, Dixit VM. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett 1998;424:41-5.
16. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997;7:1003-6.
17. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998;161:2833-40.
18. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000;60:553-9.
19. Hao C, Beguinot F, Condorelli G, Trencia A, Van Meir EG, Yong VW, et al. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apoptosis in human malignant glioma cells. Cancer Res 2001;61:1162-70.
20. Sinicrope FA, Penington RC, Tang XM. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin Cancer Res 2004;10:8284-92.
21. Matsuyama W, Yamamoto M, Higashimoto I, Oonakahara K, Watanabe M, Machida K, et al. TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus. Blood 2004;104:184-91.
22. Lee SH, Kim YK, Kim CS, Seol SK, Kim J, Cho S, et al. E2 of hepatitis C virus inhibits apoptosis. J Immunol 2005;175:8226-35.
23. Daigle I, Simon HU. Alternative functions for TRAIL receptors in eosinophils and neutrophils. Swiss Med Wkly 2001;131:231-37.
24. Robertson NM, Zangrilli JG, Steplewski A, Hastie A, Lindemeyer RG, Planeta MA, et al. Differential expression of TRAIL and TRAIL receptors in allergic asthmatics following segmental antigen challenge: evidence for a role of TRAIL in eosinophil survival. J Immunol 2002;169:5986-96.
25. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094-100.
26. Matsuyama W, Hashiguchi T, Matsumuro K, Iwami F, Hirotsu Y, Kawabata M, et al. Increased serum level of vascular endothelial growth factor in pulmonary tuberculosis. Am J Respir Crit Care Med 2000;162(3 Pt 1):1120-2.
27. Matsuyama W, Watanabe M, Shirahama Y, Oonakahara K, Higashimoto I, Yoshimura T, et al. Activation of discoidin domain receptor 1 on CD14-positive bronchoalveolar lavage fluid cells induces chemokine production in idiopathic pulmonary fibrosis. J Immunol 2005;174:6490-8.
28. Matsuyama W, Mitsuyama H, Watanabe M, Shirahama Y, Higashimoto I, Osame M, et al. Involvement of discoidin domain receptor 1 in the deterioration of pulmonary sarcoidosis. Am J Respir Cell Mol Biol 2005;33:565-73.
29. Vassina E, Leverkus M, Yousefi S, Braathen LR, Simon HU, Simon D. Increased expression and a potential anti-inflammatory role of TRAIL in atopic dermatitis. J Invest Dermatol 2005;125:746-52.
30. Rus V, Zernetkina V, Puliaev R, Cudrici C, Mathai S, Via CS. Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand by T cells from lupus patients with active disease. Clin Immunol 2005;117:48-56.
31. Robertson NM, Rosemiller M, Lindemeyer RG, Steplewski A, Zangrilli JG, Litwack G. TRAIL in the airways. Vitam Horm 2004;67:149-67.
32. Haslett C. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am J Respir Crit Care Med 1999;160(5 Pt 2):S5-11.
33. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996;156:4422-8.
34. Bloom JW, Chacko J, Lohman IC, Halonen M, Martinez FD, Miesfeld RL. Differential control of eosinophil survival by glucocorticoids. Apoptosis 2004;9:97-104.
35. Walsh GM, Sexton DW, Blaylock MG. Corticosteroids, eosinophils and bronchial epithelial cells: new insights into the resolution of inflammation in asthma. J Endocrinol 2003;178:37-43.
36. Weller PF, Plaut M, Taggart V, Trontell A. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001;108:175-83.
37. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984;63:65-81.
38. Sable-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005;143:632-8.
39. Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005;52:2926-35.
40. Mitsuyama H, Matsuyama W, Iwakawa J, Higashimoto I, Watanabe M, Osame M, et al. Increased serum vascular endothelial growth factor level in Churg-Strauss syndrome. Chest 2006;129:407-11.
41. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26-37.
42. Tatsis E, Schnabel A, Gross WL. Interferon-α, treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998; 129:370-4.
43. Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis. and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001;44:666-75.
44. Solans R, Bosch JA, Perez-Bocanegra C, Selva A, Huguet P, Alijotas J, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford) 2001;40:763-71.